 |
8 Diseases |  |
7 Trials |
|
7 Trials |  |
265 News |  |
| «12345» |
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion, Enrollment change: A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - May 9, 2017
P4, N=38, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=50 --> 38
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. (clinicaltrials.gov) - Mar 30, 2017
P3, N=355, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=50 --> 38 Recruiting --> Completed
- Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion, Trial primary completion date, Monotherapy: Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve (clinicaltrials.gov) - Jan 24, 2017
P4, N=31, Completed, Sponsor: University of Saskatchewan
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017
- || Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Enrollment closed, Combination therapy: DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=3495, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017 Recruiting --> Active, not recruiting
- Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment change, Trial termination, Trial primary completion date: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Dec 12, 2016
P2/3, N=2, Terminated, Sponsor: Mundipharma Research Limited
Recruiting --> Active, not recruiting N=130 --> 2 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Oct 2016; Recruitment issues
- Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial, Monotherapy: Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve (clinicaltrials.gov) - Nov 2, 2016
P4, N=30, Recruiting, Sponsor: University of Saskatchewan
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: Efficacy and Safety Study of QVA149 in COPD Patients (clinicaltrials.gov) - Oct 25, 2016
P3, N=356, Completed, Sponsor: Novartis Pharmaceuticals
N=130 --> 2 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Oct 2016; Recruitment issues Active, not recruiting --> Completed
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen (clinicaltrials.gov) - Sep 21, 2016
P4, N=4351, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- || Ultibro (glycopyrronium/indacaterol) / Novartis
Trial primary completion date: FLASH: Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (clinicaltrials.gov) - Sep 21, 2016
P4, N=492, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Aug 2016 --> Jan 2017
- ||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment closed: Efficacy and Safety Study of QVA149 in COPD Patients (clinicaltrials.gov) - Sep 21, 2016
P3, N=356, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial initiation date: Ultibro (clinicaltrials.gov) - Aug 31, 2016
P4, N=40, Recruiting, Sponsor: Laval University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016
- || Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Enrollment change, Combination therapy: DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (clinicaltrials.gov) - Aug 25, 2016
P=N/A, N=3500, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 N=6600 --> 3500
- Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: LAB-Card: Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 19, 2016
P4, N=48, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- || Ultibro (glycopyrronium/indacaterol) / Novartis
New P3 trial: RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative (clinicaltrials.gov) - Aug 16, 2016
P3, N=580, Not yet recruiting, Sponsor: University of Michigan
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Phase classification, Trial initiation date, Trial primary completion date: QVA Mechanistic Efficacy Study (Receptor Effects, Etc) (clinicaltrials.gov) - Aug 12, 2016
P3, N=34, Recruiting, Sponsor: Novartis Pharmaceuticals
N=6600 --> 3500 Not yet recruiting --> Recruiting | Phase classification: P4 --> P3 | Initiation date: Feb 2016 --> Jun 2016 | Trial primary completion date: Feb 2017 --> Sep 2017
- |||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open, Trial initiation date: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Aug 2, 2016
P2/3, N=130, Recruiting, Sponsor: Mundipharma Research Limited
Not yet recruiting --> Recruiting | Phase classification: P4 --> P3 | Initiation date: Feb 2016 --> Jun 2016 | Trial primary completion date: Feb 2017 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jul 2016
- ||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
Enrollment closed: TRIBUTE: 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro (clinicaltrials.gov) - Jul 1, 2016
P3, N=1534, Active, not recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jul 2016 Recruiting --> Active, not recruiting
- || Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Trial primary completion date, Combination therapy: DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=6600, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Dec 2017
- Spiriva Respimat (tiotropium bromide) / Boehringer Ingelheim, Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: INTUITIVE: Description of the Ability to Learn How to Handle Inhaler Devices in COPD (clinicaltrials.gov) - Jun 24, 2016
P4, N=30, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial initiation date: A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients (clinicaltrials.gov) - Apr 8, 2016
P4, N=404, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial primary completion date: CLAIM: Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (clinicaltrials.gov) - Mar 22, 2016
P4, N=62, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> May 2017
- Ultibro (glycopyrronium/indacaterol) / Novartis
Trial primary completion date: A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 9, 2016
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> May 2017 Trial primary completion date: Mar 2016 --> Jun 2016
- |||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open: Efficacy and Safety Study of QVA149 in COPD Patients (clinicaltrials.gov) - Mar 8, 2016
P3, N=354, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open: Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. (clinicaltrials.gov) - Mar 4, 2016
P3, N=354, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial primary completion date: FLASH: Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (clinicaltrials.gov) - Mar 4, 2016
P4, N=492, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Aug 2016
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations) (clinicaltrials.gov) - Mar 1, 2016
P3, N=3362, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Completed
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P2/3 trial: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Feb 29, 2016
P2/3, N=130, Not yet recruiting, Sponsor: Mundipharma Research Limited
- ||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment change, Trial initiation date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen (clinicaltrials.gov) - Feb 10, 2016
P4, N=4470, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=5712 --> 4470 | Initiation date: Dec 2012 --> Jun 2014 | Trial primary completion date: Oct 2015 --> May 2016
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open: Evaluation of the Efficacy and Safety of QVA149 (110/50 ?g o.d.) vs Tiotropium (18 (clinicaltrials.gov) - Jan 22, 2016
P4, N=1000, Recruiting, Sponsor: Novartis Pharmaceuticals
N=5712 --> 4470 | Initiation date: Dec 2012 --> Jun 2014 | Trial primary completion date: Oct 2015 --> May 2016 Not yet recruiting --> Recruiting
- | Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: QVA Mechanistic Efficacy Study (Receptor Effects, Etc) (clinicaltrials.gov) - Dec 18, 2015
P4, N=34, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open: ULT01: Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD (clinicaltrials.gov) - Dec 3, 2015
P4, N=40, Recruiting, Sponsor: Wouter van Geffen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: Evaluation of the Efficacy and Safety of QVA149 (110/50 ?g o.d.) vs Tiotropium (18 (clinicaltrials.gov) - Nov 14, 2015
P4, N=1000, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: ULT01: Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD (clinicaltrials.gov) - Oct 22, 2015
P4, N=40, Not yet recruiting, Sponsor: Wouter van Geffen
- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
New P3 trial: TRIBUTE: 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro (clinicaltrials.gov) - Oct 22, 2015
P3, N=1534, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- ||| Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Enrollment open, Combination therapy: DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=6600, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: Ultibro (clinicaltrials.gov) - Oct 2, 2015
P4, N=40, Not yet recruiting, Sponsor: Laval University
- ||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients (clinicaltrials.gov) - Oct 1, 2015
P4, N=404, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
New trial, Combination therapy: DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=6600, Not yet recruiting, Sponsor: AstraZeneca
- ||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: FLASH: Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (clinicaltrials.gov) - Aug 6, 2015
P4, N=492, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P3 trial: Efficacy and Safety Study of QVA149 in COPD Patients (clinicaltrials.gov) - Jul 1, 2015
P3, N=354, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P3 trial: Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. (clinicaltrials.gov) - Jul 1, 2015
P3, N=354, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Ultibro (glycopyrronium/indacaterol) / Novartis
New P4 trial: CLAIM: Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (clinicaltrials.gov) - May 13, 2015
P4, N=62, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial primary completion date: A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Apr 28, 2015
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Mar 2016
- || Ultibro (glycopyrronium/indacaterol) / Novartis
Trial primary completion date: Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (clinicaltrials.gov) - Apr 14, 2015
P4, N=710, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Sep 2016
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion, Enrollment change: FAVOR: Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (clinicaltrials.gov) - Apr 13, 2015
P4, N=88, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Sep 2016 Recruiting --> Completed | N=110 --> 88
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (clinicaltrials.gov) - Mar 7, 2015
P3, N=79, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=110 --> 88 Recruiting --> Completed
- ||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial initiation date: Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen (clinicaltrials.gov) - Feb 9, 2015
P4, N=5712, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jun 2014 --> Dec 2012
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis, Onbrez (indacaterol) / Novartis
Trial completion: Long Term Safety Study of NVA237 vs QAB149 in COPD Patients (clinicaltrials.gov) - Jan 22, 2015
P3, N=514, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Jun 2014 --> Dec 2012 Active, not recruiting --> Completed
- ||||||| Ultibro (glycopyrronium/indacaterol) / Novartis
Trial completion: A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation (clinicaltrials.gov) - Jan 5, 2015
P3, N=614, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment open, Trial primary completion date: FAVOR: Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (clinicaltrials.gov) - Oct 11, 2014
P4, N=110, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Feb 2015